Abstract:Objectives: Chemoresistance development represents a major obstacle to the successful treatment of colorectal cancer (CRC). The aim of this study was to elucidate the mechanism by which miR-506 reverses oxaliplatin chemoresistance in CRC. Methods: In this study, miR-506 levels were measured in 74 patients with colon cancer via quantitative real-time polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). We subsequently analysed the relationship between miR-506 expression and CRC patient survival via the Kaplan-Meier method. MTT assay demonstrated the fractional survival rates and cell viability of HCT116-OxR, HCT116-OxR-miR-Ctrl and HCT116-OxR-miR-506 cells treated with oxaliplatin at different concentrations. Cell proliferation and apoptosis were assessed via flow cytometry (FCM) analysis and apoptosis assay. MDR1 mRNA expression and P-gp protein expression were assessed via qRT-PCR and Western blotting (WB) respectively. Immunofluorescence (IF) staining demonstrated P-gp expression in HCT116-OxR and HCT116-OxR-miR-506 cells. qRT-PCR and WB were used to detect Wnt/beta-catenin pathway activity after miR-506 overexpression. Results: In the present study, in ISH and qRT-PCR results demonstrated that miR-506 is weakly expressed in chemoresistant CRC tissues. The low miR-506 expression group exhibited lower 5-year OS and lower 5-year RFS than the high miR-506 expression group. miR-506 overexpression inhibited cell growth and increased oxaliplatin-induced cell apoptosis in HCT116-OxR cells, as shown via FCM and apoptosis assay. We subsequently noted low MDR1/P-gp expression in HCT116-OxR-miR-506 cells via qRT-PCR, WB and IF. Lastly, we demonstrated low MDR1/P-gp expression in HCT116-OxR-miR--506 cells via inhibition of the Wnt/beta-catenin by WB, MTT and FCM analysis. Conclusion: Taken together, the findings of our study demonstrate that miR-506 overexpression in HCT116-OxR cells enhances oxaliplatin sensitivity by inhibiting MDR1/P-gp expression via down-regulation of the Wnt/beta-catenin pathway and thus provide a rationale for the development of miRNA-based strategies to reverse oxaliplatin resistance in CRC cells.

Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer

Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer

CQ Synergistically Sensitizes Human Colorectal Cancer Cells to SN-38/CPT-11 Through Lysosomal and Mitochondrial Apoptotic Pathway Via P53-Ros Cross-Talk.

Ursolic Acid Synergistically Enhances the Therapeutic Effects of Oxaliplatin in Colorectal Cancer

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer

Neural Precursor Cell Expressed, Developmentally Downregulated 8-Activating Enzyme Inhibitor Mln4924 Sensitizes Colorectal Cancer Cells to Oxaliplatin by Inducing Dna Damage, G2 Cell Cycle Arrest and Apoptosis

Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas

Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer Through the Mir-543/Pten/akt/mtor Pathway

The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer

Combined Olaparib and Oxaliplatin Inhibits Tumor Proliferation by Cell Cycle Arrest and Cell Apoptosis in XRCC2-defecient Colorectal Cancer

Enhancement of Oxaliplatin-Induced Cell Apoptosis and Tumor Suppression by 3-Methyladenine in Colon Cancer

The Synergistic Effects of Oxaliplatin and Piperlongumine on Colorectal Cancer Are Mediated by Oxidative Stress

Combination of bazedoxifene with chemotherapy and SMAC-mimetics for the treatment of colorectal cancer

Enhanced Chemosensitivity to CPT-11 in Colorectal Carcinoma Xenografts by Small Hairpin RNA Interference Targeting PLK1.

Dual PI3K/mTOR Inhibitor BEZ235 combined with BMS-1166 Promoting Apoptosis in Colorectal Cancer

Combined Olaparib and Oxaliplatin Inhibits Tumor Proliferation and Induces G(2)/M Arrest and Gamma-H2ax Foci Formation in Colorectal Cancer

DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Nanocomplexes Loaded with Mir-128-3p for Enhancing Chemotherapy Effect of Colorectal Cancer Through Dual-Targeting Silence the Activity of PI3K/AKT and MEK/ERK Pathway.

miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.

Berberine and Oligomeric Proanthocyanidins Exhibit Synergistic Efficacy Through Regulation of PI3K-Akt Signaling Pathway in Colorectal Cancer